Clinical Evidence

GyroStim is indicated for treatment of balance disorders and vestibular dysfunction, supporting its clinical use across a broad range of neurological conditions known to benefit from vestibular rehabilitation therapy (VRT)—including concussion, traumatic brain injury (TBI), stroke, Parkinson’s disease, multiple sclerosis (MS), cerebral palsy, autism spectrum disorder (ASD), postural orthostatic tachycardia syndrome (POTS), and other disorders affecting vestibular function and sensorimotor integration.

Below is a summary of clinical evidence demonstrating GyroStim’s effectiveness in two of the most common conditions it treats—concussion / mTBI and vestibular dysfunction.

Clinical Evidence:

mTBI / Persistent Post-Concussion Syndrome (PPCS)

The clinical evidence presented below* is the summary of a chart review of two groups of adult patients with a history of mTBI, loss of consciousness for less than 30 minutes, and with a current diagnosis of persistent post-concussion syndrome (PPCS). The chart review compares the outcome data for patients who received standard of care (SOC) with patients who received GyroStim technology-assisted multimodal neurorehabilitation in addition to SOC.

Group 1: SOC
Patients in Group 1 received SOC treatment for PPCS / mTBI. Click here for details.
Group 2: SOC + GyroStim
Patients in Group 2 received the same SOC treatment as Group 1, but patients in Group 2 also received GyroStim neurorehabilitation. Click here for details.

All patients followed the same protocols for intake, balance education, and training for at-home daily therapy and exercise routines.
All patients were assessed with SCAT5 for pre and post intervention evaluation.
- SCAT5 (Sport Concussion Assessment Tool, 5th Edition) is a standardized, evidence-based assessment tool used to evaluate the presence and severity of concussion-related symptoms.
- The SCAT5 Symptom Severity Score has a total range from 0 to 132, where 0 indicates no symptoms and 132 represents the maximum possible symptoms.
All patients followed the same SOC treatment protocols for PPCS.
Group 2 received GyroStim neurorehabilitation for PPCS, Group 1 did not.

Group 1: SOC

The Group 1: SOC SCAT5 Scores chart shows average scores from the SCAT5 assessment before and after SOC intervention.

Average pre-treatment SCAT5 score was 67.25
Average post-treatment SCAT5 score was 61
Average improvement (reduction in score) for SOC was 6.25 points.

Group 2: SOC + GyroStim

The Group 2: SOC + GyroStim SCAT5 Scores chart shows average scores from the SCAT5 assessment before and after SOC plus GyroStim intervention.

Average pre-treatment SCAT5 score was 86.5
Average post-treatment SCAT5 score was 34.75
Average improvement (reduction in score) for SOC plus GyroStim was 51.75 points.

SCAT5 Score Comparison

The SCAT5 Symptom Severity Score chart compares the difference in outcomes between Group1 and Group 2:

Group 1: Patients treated only with SOC showed a relatively small clinical improvement in symptoms associated with PPCS / mTBI, as evidenced by an average SCAT5 score reduction (improvement in symptoms) of 6.25 points.
Group 2: Patients treated with GyroStim in addition to SOC showed a relatively large recovery from symptoms associated with PPCS / mTBI, as evidenced by an average SCAT5 score reduction of 51.75 points—more than 8x greater than the SCAT5 score reduction observed in Group 1.

The SCAT5 score comparison of Group 1 and Group 2 shows that Group 2 experienced 8x greater recovery than Group 1.

Therapeutic Dose-Response Comparison

Neurorehabilitation is a multidisciplinary approach with therapy programs customized to meet each patient’s unique needs. As a result, treatment duration, session count, and therapy frequency typically varies among individuals. Therefore, the most accurate way to evaluate and compare therapeutic effectiveness is by calculating the therapeutic dose-response per session—the measurable average amount of recovery achieved during each in-clinic, neurorehabilitation session.

The Therapeutic Dose-Response Per Treatment Session chart compares the average therapeutic dose-response per therapy session observed in Group 1 and Group 2. The Group 1 and 2 Recovery Trajectories chart shows the trajectory for the average amount of recovery per session for each Group.

Group 1 had an average of 20 SOC therapy sessions (in-clinic visits) with an average therapy frequency of 5.2 days over an average treatment duration of 104 days. The SCAT5 score change from the pre to post test shows a total average reduction in symptoms of 6.25 points, resulting in a relatively small therapeutic dose-response for SOC of 0.31 points per therapy session.
Group 2 had an average of 10 SOC + GyroStim therapy sessions (in-clinic visits) with an average therapy frequency of 8.2 days over an average treatment duration of 82 days. The SCAT5 score change from the pre to post test shows a total average reduction in symptoms of 51.75 points, resulting in a relatively large therapeutic dose-response for SOC + GyroStim of 5.18 points per therapy session.

The Therapeutic Dose-Response chart shows that patients in Group 2 achieved approximately 17× greater therapeutic dose-response than patients in Group 1.

The SCAT5 Score Improvement Trend chart further illustrates how this substantial increase in treatment effectiveness translates to faster, more complete recovery for patients in Group 2.

Balance Comparison

The Modified Balance Error Scoring System (mBESS) measures balance and postural control on a scale of 0 to 30, with higher scores indicating greater impairment.

The mBESS Improvement chart shows that patients in Group 1 achieved an average balance improvement of 23%, while those in Group 2 achieved an average improvement of 58%.

These results demonstrate that patients in Group 2 experienced more than double the improvement in postural control and balance compared to those in Group 1.

Conclusion

Persistent Post-Concussion Syndrome (PPCS) remains one of the most challenging conditions to treat effectively using traditional neurorehabilitation methods. Standard therapies often fall short in resolving persistent vestibular, sensorimotor processing, and cognitive deficits, leading to prolonged recovery, functional limitations, and reduced quality of life.

This retrospective chart review evaluated outcomes in patients diagnosed with PPCS who received either Standard of Care (SOC) neurorehabilitation alone or GyroStim robotic-assisted multimodal neurorehabilitation integrated with SOC.

Results demonstrated that patients treated with GyroStim + SOC achieved significantly greater improvements than those receiving SOC alone—including more than double the improvement in balance and postural control, an 8× greater reduction in symptom severity, and a 17× higher therapeutic dose-response per session.

These findings indicate that integrating GyroStim treatment into SOC protocols can significantly enhance treatment efficiency and effectiveness, accelerate recovery trajectories, and promote more complete functional restoration in patients with PPCS compared to SOC alone.

*Clinical evidence provided by:

Heyser Chiropractic Neurology

Bill G. Heyser D.C., M.D., DABCN

Clinical Evidence:

Balance Disorders and Vestibular Dysfunction

The clinical evidence presented below* is based on a chart review comparing two groups of adult patients diagnosed with vestibular dysfunction. Data were compiled according to treatment type into two cohorts: Standard of Care (SOC) and GyroStim + Standard of Care (GS + SOC).

SOC: Patients received targeted vestibular rehabilitation therapy (VRT) for vestibular dysfunction.
GS + SOC: Patients received the same targeted VRT as the SOC group, supplemented with GyroStim multimodal neurorehabilitation therapy for the treatment of vestibular dysfunction.

Both groups included adult patients with vestibular dysfunction secondary to conditions such as concussion/mTBI, stroke, BPPV, PPPD, vestibular neuritis, unilateral vestibular loss (UVL), bilateral vestibular loss (BVL), and mal de débarquement syndrome (MdDS).

All participants completed standardized pre- and post-intervention assessments using validated, gold-standard clinical measures: Sensory Organization Test (SOT), Dizziness Handicap Inventory (DHI), Activities-specific Balance Confidence Scale (ABC), and Modified Dynamic Gait Index (mDGI).

To ensure consistency and comparability, both groups followed uniform intake protocols, received balance education, and were prescribed standardized home exercise programs.

The Preliminary Clinical Data Comparison sheet compiles outcomes from these four clinical assessments used to evaluate vestibular dysfunction in both treatment groups.

Findings from this chart review demonstrate that patients receiving GyroStim technology-assisted multimodal neurorehabilitation in conjunction with standard of care experienced a significantly accelerated rate of recovery, achieving clinical discharge approximately four times faster than those treated with standard of care alone.

*Clinical evidence provided by:

AVORA Health

Kimberly Fox, PT, DPT

Clinical Evidence

Clinical Evidence:

mTBI / Persistent Post-Concussion Syndrome (PPCS)

Group 1: SOC

Group 2: SOC + GyroStim

SCAT5 Score Comparison

Therapeutic Dose-Response Comparison

Balance Comparison

Conclusion

Clinical Evidence:

Balance Disorders and Vestibular Dysfunction

Disclaimer

Stay up to date with GyroStim:

Clinical Evidence

Clinical Evidence: mTBI / Persistent Post-Concussion Syndrome (PPCS)

Group 1: SOC

Group 2: SOC + GyroStim

SCAT5 Score Comparison

Therapeutic Dose-Response Comparison

Balance Comparison

Conclusion

Clinical Evidence: Balance Disorders and Vestibular Dysfunction

Stay up to date with GyroStim:

Clinical Evidence:

mTBI / Persistent Post-Concussion Syndrome (PPCS)

Clinical Evidence:

Balance Disorders and Vestibular Dysfunction